JAZZ Jazz Pharmaceuticals plc - Ordinary Shares
$254.94
Price · Aug 19, 2026
Fundamentals as of Aug 3, 2026
52W Range
$118–$265
93% of range
Analyst Rating
BUY
26 analysts
Price Target
$281
+10% upside
P/E (TTM)
-29.1
ROE
—
Net Profit Margin
—
About Jazz Pharmaceuticals plc - Ordinary Shares Company overview from Wikipedia
Jazz Pharmaceuticals plc is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Read more
Jazz Pharmaceuticals plc (a merger of Jazz Pharmaceuticals, Inc. and Azur Pharma plc) is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
One of the company's considerable products is the United States Food and Drug Administration (FDA) approved drug Xyrem (sodium oxybate), the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid (GHB). In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness (EDS) in narcolepsy as well as obstructive sleep apnea (OSA). In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.
In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.
The company is also a member of the Pharmaceutical Research and Manufacturers of America (PhRMA).
Company history and acquisitions
2010–2019
On 18 February 2010, the FDA accepted a new drug application for JZP-6 (Sodium oxybate) for the treatment of Fibromyalgia. In the following December, a new patent was issued for Sodium Oxybate.
On September 19, 2011, Jazz Pharmaceuticals merged with Irish Azur Pharma plc to form Jazz Pharmaceuticals plc. The Azur Pharma seat in Dublin became the headquarters of the combined company. Azur Pharma had been marketing specialty pharmaceutical products in the central nervous system (CNS) and women's health areas with US operations in Philadelphia.
On 26 April 2012, the company acquired EUSA Pharma for $650 million (plus $50 million in milestone payments). In September, the company sold its Women's Health business to Meda for $95 million. In December, the company began clinical trial of intravenous Erwinaze in patients with Acute Lymphoblastic Leukemia.
In January 2014, the company announced it would acquire the rare disease drug developer Gentium SpA and its lead product Defitelio for $1 billion.
In May 2016, the company announced it would acquire Alizé Pharma II for $20.5 million. At the end of the same month, the company announced its then largest acquisition, with the purchase of Celator Pharmaceuticals for $1.5 billion. As a result, Jazz obtained the rights to breakthrough therapy Vyxeos (liposomal daunorubicin and cytarabine) for treatment of acute myeloid leukemia.
In August 2019, the company announced it would acquire Cavion Inc. for up to $310 million.
2020–present
In January 2021, Jazz announced it would acquire cannabis-focused medicinal drug company GW Pharmaceuticals for US$7.2 billion. This acquisition added the medication Epidiolex (cannabidiol), developed to treat severe epilepsy syndromes, to the company's portfolio.
In November 2025, Jazz Pharmaceuticals announced positive results from its Phase 3 trial for its cancer drug, Ziihera, a potential treatment for advanced gastroesophageal cancer.
Acquisition history
The following is an illustration of the company's mergers, acquisitions, spin-offs and historical predecessors:
== References ==
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
JAZZ Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$254.94
Market Cap
—
P/E (TTM)
-29.1
EPS (TTM)
$-5.84
Revenue (TTM)
$4.27B
Div Yield
—
ROE
—
Debt/Equity
—
52W Range
$118 – $265
JAZZ Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
10-Year Performance Revenue, net income, margins and EPS trends
Revenue & Net Income
$4.27B
2016-12-31
→
2025-12-31
EPS
$-5.84
2016-12-31
→
2025-12-31
Free Cash Flow
—
Margins
—
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Metric
5Y trend
JAZZ
Peer Median
P/E (TTM)
-29.1
530.6
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Metric
5Y trend
JAZZ
Peer Median
Financial Health Debt, liquidity, solvency — balance sheet strength
Metric
5Y trend
JAZZ
Peer Median
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Metric
5Y trend
JAZZ
Peer Median
Revenue YoY
4.9%
—
Revenue CAGR 3Y
5.3%
—
Revenue CAGR 5Y
12.5%
—
EPS YoY
41.8%
—
Net Income YoY
35.0%
—
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Metric
5Y trend
JAZZ
Peer Median
JAZZ Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
BUY
26 analysts
- Strong Buy 7 26.9%
- Buy 17 65.4%
- Hold 2 7.7%
- Sell 0 0.0%
- Strong Sell 0 0.0%
12-Month Price Target
20 analysts · 2026-08-15
Median
$285.00
Now
$254.94
Low
$196.00
High
$315.00
Median target
$285.00
+11.8%
Mean target
$281.10
+10.3%
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-0.06%
| Period | EPS Actual | EPS Est | Surprise |
|---|---|---|---|
| June 30, 2026 | $5.71 | $6.30 | -0.59% |
| March 31, 2026 | $6.34 | $4.66 | 1.7% |
| Dec. 31, 2025 | $6.64 | $6.65 | -0.01% |
| Sept. 30, 2025 | $8.13 | $6.04 | 2.1% |
| June 30, 2025 | $-8.25 | $-7.76 | -0.49% |
| March 31, 2025 | $1.68 | $4.75 | -3.1% |
Peer comparison (GICS sub-industry) Key metrics vs sector peers
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| JAZZ | — | -29.1 | 4.9% | — | — | — |
| GHRS | — | — | — | — | — | — |
| PRGO | $1.92B | -1.4 | -2.8% | -33.5% | -38.5% | 35.1% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement 14
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B | $2.36B | $2.16B | $1.89B | $1.62B | $1.49B | $1.32B | $1.17B | |
| R&D Expense | · | · | · | · | · | · | $300M | $227M | $198M | $162M | $135M | $85M | |
| SG&A Expense | $1.81B | $1.39B | $1.34B | $1.42B | $1.45B | $854M | $737M | $684M | $544M | $503M | $449M | $406M | |
| Operating Expenses | $4.70B | $3.35B | $3.26B | $3.72B | $2.92B | $1.99B | $1.63B | $1.28B | $1.09B | $896M | $817M | $977M | |
| Operating Income | $-430M | $717M | $579M | $-66M | $170M | $378M | $532M | $615M | $529M | $592M | $508M | $196M | |
| Interest Income | $86M | $106M | $65M | $12M | $2M | $11M | $20M | $17M | $4M | · | · | · | |
| Other Non-op | · | · | · | · | · | · | · | · | · | · | $1M | $9M | |
| Pretax Income | $-628M | $470M | $298M | $-373M | $-113M | $275M | $454M | $529M | $441M | $532M | $436M | $152M | |
| Income Tax | $-272M | $-91M | $-120M | $-159M | $216M | $34M | $-73M | $80M | $-48M | $135M | $106M | $94M | |
| Net Income | $-356M | $560M | $415M | $-224M | $-330M | $239M | $523M | $447M | $488M | $397M | $330M | $58M | |
| EPS (Basic) | $-5.84 | $9.06 | $6.55 | $-3.58 | $-5.52 | $4.28 | $9.22 | $7.45 | $8.13 | $6.56 | $5.38 | $0.98 | |
| EPS (Diluted) | $-5.84 | $8.65 | $6.10 | $-3.58 | $-5.52 | $4.22 | $9.09 | $7.30 | $7.96 | $6.41 | $5.23 | $0.93 | |
| Shares (Basic) | 60,981,000 | 61,838,000 | 63,291,000 | 62,539,000 | 59,694,000 | 55,712,000 | 56,749,000 | 59,976,000 | 60,018,000 | 60,500,000 | 61,232,000 | 59,746,000 | |
| Shares (Diluted) | 60,981,000 | 66,007,000 | 72,066,000 | 62,539,000 | 59,694,000 | 56,517,000 | 57,550,000 | 61,221,000 | 61,317,000 | 61,870,000 | 63,036,000 | 62,614,000 |
Balance Sheet 26
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.39B | $2.41B | $1.51B | $881M | $591M | $1.06B | $637M | $310M | $386M | $366M | $989M | $684M | |
| Receivables | $831M | $717M | $706M | $651M | $563M | $396M | $356M | $264M | $224M | $234M | $210M | $186M | |
| Inventory | $417M | $480M | $597M | $714M | $1.07B | $95M | $79M | $53M | $43M | $34M | $19M | $30M | |
| Prepaid Expense | $152M | $177M | $185M | $92M | $131M | $62M | $39M | $25M | $23M | $25M | $21M | $13M | |
| Other Current Assets | $324M | $262M | $321M | $267M | $252M | $152M | $79M | $68M | $77M | $29M | $19M | $21M | |
| Current Assets | $4.17B | $4.63B | $3.44B | $2.61B | $2.61B | $2.84B | $1.63B | $1.23B | $968M | $748M | $1.26B | $1.02B | |
| PP&E (Net) | · | · | · | · | · | $128M | $132M | $200M | $170M | $107M | $86M | $58M | |
| PP&E (Gross) | · | · | · | · | · | $196M | $187M | $250M | $211M | $140M | $109M | $74M | |
| Accum. Depreciation | · | · | · | · | · | $68M | $55M | $50M | $41M | $32M | $24M | $15M | |
| Goodwill | $1.83B | $1.72B | $1.75B | $1.69B | $1.83B | $958M | $920M | $928M | $948M | $894M | $657M | $703M | |
| Intangibles | $4.43B | $4.76B | $5.42B | $5.79B | $7.15B | $2.20B | $2.44B | $2.73B | $2.98B | $3.01B | $1.19B | $1.44B | |
| Other Non-current Assets | $99M | $114M | $67M | $55M | $41M | $26M | $48M | $43M | $16M | $14M | $9M | $16M | |
| Total Assets | $11.66B | $12.01B | $11.39B | $10.84B | $12.30B | $6.54B | $5.54B | $5.20B | $5.12B | $4.80B | $3.33B | $3.34B | |
| Accounts Payable | $122M | $78M | $103M | $91M | $100M | $27M | $46M | $41M | $24M | $22M | $22M | $25M | |
| Accrued Liabilities | $1.03B | $911M | $794M | $803M | $666M | $353M | $270M | $265M | $199M | $193M | $164M | $164M | |
| Current Liabilities | $2.24B | $1.04B | $1.54B | $933M | $809M | $654M | $364M | $345M | $294M | $257M | $227M | $217M | |
| Capital Leases | $51M | $39M | $59M | $72M | $87M | $140M | $151M | $0 | · | · | · | · | |
| Deferred Tax | $594M | $677M | $848M | $944M | $1.30B | $130M | $224M | $309M | $383M | $557M | $283M | $375M | |
| Other Non-current Liabilities | $124M | $87M | $105M | $107M | $117M | $101M | $109M | $219M | $177M | $113M | $69M | $38M | |
| Long-term Debt | $5.36B | $6.11B | $5.71B | $5.72B | $6.05B | $2.09B | $1.61B | $1.60B | $1.58B | $2.03B | $1.19B | $1.34B | |
| Common Stock | $0 | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | |
| Retained Earnings | $646M | $1.13B | $879M | $734M | $830M | $1.16B | $1.07B | $841M | $918M | $529M | $303M | $35M | |
| AOCI | $-569M | $-948M | $-842M | $-1.13B | $-400M | $-134M | $-223M | $-198M | $-141M | $-317M | $-267M | $-122M | |
| Stockholders' Equity | $4.32B | $4.09B | $3.74B | $3.09B | $3.97B | $3.66B | $3.11B | $2.76B | $2.71B | $1.88B | $1.71B | $1.37B | |
| Liabilities + Equity | $11.66B | $12.01B | $11.39B | $10.84B | $12.30B | $6.54B | $5.54B | $5.20B | $5.12B | $4.80B | $3.33B | $3.34B | |
| Shares Outstanding | 61,400,000 | 60,600,000 | 62,255,000 | 63,214,000 | 61,633,000 | 56,171,000 | 56,140,000 | 57,704,000 | 58,898,000 | 59,820,000 | 61,305,000 | 60,643,000 |
Cash Flow 12
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $42M | $33M | $30M | $30M | $27M | $19M | $15M | $15M | $13M | $12M | $10M | · | |
| Stock-based Comp | $291M | $248M | $227M | $222M | $189M | $121M | $111M | $102M | $107M | $99M | $92M | $70M | |
| Deferred Tax | $-445M | $-208M | $-260M | $-292M | $69M | $-137M | $-237M | $-89M | $-226M | $-41M | $-68M | $-49M | |
| Amort. of Intangibles | $655M | $627M | $608M | $599M | $526M | $260M | $355M | $201M | $152M | $102M | $98M | $127M | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | $2M | $2M | |
| Operating Cash Flow | $1.36B | $1.40B | $1.09B | $1.27B | $779M | $900M | $776M | $799M | $693M | $592M | $532M | $408M | |
| CapEx | $59M | $38M | $24M | $29M | $28M | $15M | $40M | $20M | $29M | $10M | $36M | $36M | |
| Investing Cash Flow | $-1.51B | $-508M | $-163M | $-446M | $-5.21B | $-1.01B | $-155M | $-394M | $-269M | $-1.75B | $-2M | $-1.07B | |
| Stock Repurchased | $125M | $311M | $270M | $54.0K | $0 | $147M | $301M | $524M | $99M | $278M | $62M | $42M | |
| Financing Cash Flow | $-873M | $21M | $-305M | $-529M | $3.97B | $528M | $-294M | $-479M | $-409M | $541M | $-214M | $711M | |
| Net Change in Cash | $-1.02B | $907M | $625M | $290M | $-466M | $420M | $328M | $-76M | $20M | $-623M | $305M | $48M | |
| Taxes Paid | $122M | $115M | $178M | · | · | · | · | · | · | · | · | · |
Growth Rates 7
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 4.9% | 6.1% | 4.8% | 18.3% | 30.9% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 5.3% | 9.6% | 17.5% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 12.5% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | · | 41.8% | · | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | · | · | 13.1% | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | · | 35.0% | · | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | · | · | 20.2% | · | · | · | · | · | · | · | · | · |
Valuation (TTM) 5
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B | $2.36B | $2.16B | $1.89B | $1.62B | $1.49B | $1.32B | $1.17B | |
| Net Income TTM | $-356M | $560M | $415M | $-224M | $-330M | $239M | $523M | $447M | $488M | $397M | $330M | $58M | |
| P/E | -29.1 | 14.2 | 20.2 | -44.5 | -23.1 | 39.1 | 16.4 | 17.0 | 16.9 | 17.0 | 26.9 | 176.1 | |
| P / Tangible Book | · | · | · | · | · | 18.3 | · | · | · | · | · | · | |
| Earnings Yield | -3.4% | 7.0% | 5.0% | -2.2% | -4.3% | 2.6% | 6.1% | 5.9% | 5.9% | 5.9% | 3.7% | 0.57% |
Income Statement 13
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.21B | $1.07B | $1.20B | $1.13B | $1.05B | $898M | $1.09B | $1.05B | $1.02B | $902M | $1.01B | $972M | $957M | $893M | $972M | $941M | |
| SG&A Expense | $389M | $353M | $406M | $531M | $358M | $514M | $369M | $326M | $339M | $352M | $396M | $308M | $341M | $298M | $383M | $358M | |
| Operating Expenses | $960M | $732M | $943M | $1.07B | $1.73B | $954M | $897M | $795M | $824M | $836M | $889M | $800M | $800M | $767M | $1.24B | $916M | |
| Operating Income | $248M | $337M | $255M | $58M | $-686M | $-56M | $191M | $260M | $199M | $66M | $122M | $172M | $158M | $126M | $-263M | $25M | |
| Interest Income | $25M | $23M | $20M | $19M | $19M | $28M | $32M | $26M | $25M | $23M | $21M | $19M | $15M | $11M | $7M | $4M | |
| Pretax Income | $211M | $299M | $208M | $9M | $-736M | $-110M | $133M | $201M | $138M | $-2M | $62M | $100M | $82M | $55M | $-340M | $-60M | |
| Income Tax | $18M | $6M | $5M | $-242M | $-17M | $-18M | $-58M | $-15M | $-31M | $12M | $-33M | $-47M | $-24M | $-15M | $-100M | $-43M | |
| Net Income | $193M | $293M | $203M | $251M | $-718M | $-92M | $191M | $215M | $169M | $-15M | $94M | $147M | $104M | $69M | $-241M | $-20M | |
| EPS (Basic) | $3.05 | $4.73 | $3.28 | $4.14 | $-11.74 | $-1.52 | $3.11 | $3.50 | $2.68 | $-0.23 | $1.50 | $2.33 | $1.63 | $1.09 | $-3.86 | $-0.31 | |
| EPS (Diluted) | $2.78 | $4.43 | $3.34 | $4.08 | $-11.74 | $-1.52 | $2.97 | $3.42 | $2.49 | $-0.23 | $1.40 | $2.14 | $1.52 | $1.04 | $-3.85 | $-0.31 | |
| Shares (Basic) | 63,200,000 | 61,900,000 | -121,888,000 | 60,696,000 | 61,200,000 | 61,000,000 | -124,995,000 | 61,414,000 | 62,882,000 | 62,537,000 | -127,308,000 | 63,114,000 | 63,991,000 | 63,494,000 | -124,547,000 | 62,785,000 | |
| Shares (Diluted) | 69,400,000 | 66,100,000 | -122,798,000 | 61,606,000 | 61,200,000 | 61,000,000 | -129,329,000 | 63,174,000 | 69,625,000 | 62,537,000 | -146,538,000 | 71,293,000 | 73,540,000 | 73,771,000 | -126,584,000 | 62,785,000 | |
| EBITDA | $248M | $337M | · | $58M | $-686M | $-56M | · | $260M | $199M | $66M | · | $172M | $158M | $126M | · | $25M |
Balance Sheet 24
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.62B | $1.84B | $1.39B | $1.33B | $1.19B | $1.86B | $2.41B | $2.22B | $1.36B | $1.44B | · | $1.34B | $1.28B | $1.17B | · | $839M | |
| Receivables | $881M | $836M | $831M | $764M | $714M | $653M | $717M | $724M | $698M | $707M | · | $628M | $610M | $624M | · | $601M | |
| Inventory | $443M | $438M | $417M | $483M | $505M | $493M | $480M | $539M | $543M | $577M | · | $612M | $657M | $675M | · | $728M | |
| Prepaid Expense | $200M | $150M | $152M | $147M | $164M | $150M | $177M | $155M | $134M | $123M | · | $110M | $107M | $73M | · | $93M | |
| Other Current Assets | $244M | $285M | $324M | $315M | $298M | $260M | $262M | $354M | $326M | $315M | · | $310M | $272M | $245M | · | $250M | |
| Current Assets | $3.97B | $4.58B | $4.17B | $3.76B | $3.35B | $4.13B | $4.63B | $4.39B | $3.68B | $3.54B | · | $3.25B | $3.01B | $2.78B | · | $2.57B | |
| Goodwill | $1.80B | $1.80B | $1.83B | $1.83B | $1.84B | $1.76B | $1.72B | $1.80B | $1.74B | $1.74B | · | $1.71B | $1.74B | $1.72B | · | $1.59B | |
| Intangibles | $4.03B | $4.20B | $4.43B | $4.57B | $4.77B | $4.72B | $4.76B | $5.14B | $5.08B | $5.24B | · | $5.42B | $5.71B | $5.76B | · | $5.57B | |
| Other Non-current Assets | $86M | $95M | $99M | $103M | $121M | $117M | $114M | $75M | $71M | $71M | · | $76M | $66M | $64M | · | $35M | |
| Total Assets | $11.08B | $11.86B | $11.66B | $11.36B | $10.94B | $11.53B | $12.01B | $12.26B | $11.36B | $11.33B | · | $11.20B | $11.26B | $11.05B | · | $10.38B | |
| Accounts Payable | $128M | $100M | $122M | $152M | $89M | $96M | $78M | $85M | $97M | $81M | · | $110M | $98M | $125M | · | $102M | |
| Accrued Liabilities | $1.03B | $1.02B | $1.03B | $1.00B | $875M | $1.06B | $911M | $859M | $801M | $827M | · | $770M | $748M | $712M | · | $668M | |
| Current Liabilities | $2.23B | $2.25B | $2.24B | $2.27B | $2.07B | $1.22B | $1.04B | $1.03B | $1.56B | $1.56B | · | $1.57B | $945M | $909M | · | $813M | |
| Capital Leases | $44M | $47M | $51M | $53M | $55M | $39M | $39M | $71M | $68M | $56M | · | $62M | $66M | $72M | · | $73M | |
| Deferred Tax | $529M | $548M | $594M | $629M | $682M | $671M | $677M | $792M | $775M | $810M | · | $841M | $911M | $932M | · | $934M | |
| Other Non-current Liabilities | $141M | $162M | $125M | $109M | $94M | $91M | $87M | $111M | $99M | $97M | · | $127M | $127M | $109M | · | $124M | |
| Long-term Debt | $4.35B | $5.35B | $5.36B | $5.36B | $5.36B | $5.37B | $6.11B | $6.11B | $5.71B | $5.71B | · | $5.72B | $5.72B | $5.72B | · | $5.73B | |
| Total Debt | $4.35B | $5.35B | · | $5.36B | $5.36B | $5.37B | · | $6.11B | $5.71B | $5.71B | · | $5.72B | $5.72B | $5.72B | · | $5.73B | |
| Common Stock | $0 | $0 | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | · | $6.0K | $6.0K | $6.0K | · | $6.0K | |
| Retained Earnings | $1.13B | $939M | $646M | $443M | $191M | $1.03B | $1.13B | $936M | $871M | $864M | · | $884M | $812M | $803M | · | $974M | |
| AOCI | $-662M | $-651M | $-569M | $-570M | $-486M | $-786M | $-948M | $-603M | $-888M | $-882M | · | $-1.04B | $-867M | $-980M | · | $-1.62B | |
| Stockholders' Equity | $4.80B | $4.53B | $4.32B | $3.96B | $3.71B | $4.17B | $4.09B | $4.17B | $3.76B | $3.70B | $3.74B | $3.49B | $3.53B | $3.34B | $3.09B | $2.75B | |
| Liabilities + Equity | $11.08B | $11.86B | $11.66B | $11.36B | $10.94B | $11.53B | $12.01B | $12.26B | $11.36B | $11.33B | · | $11.20B | $11.26B | $11.05B | · | $10.38B | |
| Shares Outstanding | 64,800,000 | 62,700,000 | 61,435,000 | 60,740,000 | 60,640,000 | 61,623,000 | 60,631,000 | 60,443,000 | 61,745,000 | 63,028,000 | 62,255,000 | 62,945,000 | · | · | 63,214,000 | · |
Cash Flow 10
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $73M | $74M | $71M | $88M | $65M | $68M | $70M | $60M | $57M | $61M | $53M | $56M | $61M | $56M | $62M | $57M | |
| Deferred Tax | $-39M | $-66M | $-63M | $-271M | $-66M | $-44M | $-2M | $-64M | $-75M | $-66M | $-36M | $-79M | $-79M | $-66M | $-145M | $-65M | |
| Amort. of Intangibles | $170M | $172M | $170M | $168M | $162M | $154M | $159M | $157M | $155M | $156M | $152M | $155M | $152M | $150M | $137M | $141M | |
| Operating Cash Flow | $416M | $408M | $363M | $475M | $89M | $430M | $399M | $399M | $331M | $267M | $167M | $307M | $297M | $321M | $342M | $418M | |
| CapEx | $18M | $20M | $17M | $15M | $13M | $14M | $13M | $11M | $7M | $7M | $10M | $4M | $6M | $4M | $9M | $-5M | |
| Investing Cash Flow | $355M | $123M | $-372M | $-328M | $-641M | $-169M | $-193M | $214M | $-257M | $-272M | $102M | $-174M | $-86M | $-5M | $-324M | $5M | |
| Stock Repurchased | · | · | $0 | $0 | · | · | $0 | $150M | · | · | $100M | $74M | · | · | $0 | $0 | |
| Financing Cash Flow | $-994M | $-78M | $75M | $-11M | $-125M | $-814M | $-8M | $246M | $-161M | $-57M | $-100M | $-78M | $-97M | $-30M | $20M | $-289M | |
| Net Change in Cash | $-224M | $452M | $66M | $136M | $-672M | $-551M | $195M | $862M | $-88M | $-63M | $171M | $53M | $114M | $286M | $42M | $128M | |
| Free Cash Flow | · | $388M | · | · | · | $416M | · | · | · | $260M | · | · | · | $317M | · | · |
Profitability 7
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 20.5% | 31.5% | · | 5.1% | -65.6% | -6.2% | · | 24.7% | 19.5% | 7.3% | · | 17.7% | 16.5% | 14.1% | · | 2.6% | |
| Net Margin | 16.0% | 27.4% | · | 22.3% | -68.7% | -10.3% | · | 20.4% | 16.5% | -1.6% | · | 15.1% | 10.9% | 7.8% | · | -2.1% | |
| Pretax Margin | 17.5% | 28.0% | · | 0.80% | -70.3% | -12.2% | · | 19.0% | 13.5% | -0.18% | · | 10.2% | 8.5% | 6.2% | · | -6.4% | |
| EBITDA Margin | 20.5% | 31.5% | · | 5.1% | -65.6% | -6.2% | · | 24.7% | 19.5% | 7.3% | · | 17.7% | 16.5% | 14.1% | · | 2.6% | |
| ROA | 1.8% | 2.5% | · | 2.1% | -6.4% | -0.81% | · | 1.8% | 1.5% | -0.13% | · | 1.4% | 0.93% | 0.61% | · | -0.17% | |
| ROE | 4.5% | 6.7% | · | 6.2% | -19.2% | -2.4% | · | 5.6% | 4.6% | -0.42% | · | 4.7% | 3.1% | 2.0% | · | -0.59% | |
| ROIC | 2.5% | 3.3% | · | 17.2% | -7.4% | -0.49% | · | 2.7% | 2.6% | 5.8% | · | 2.8% | 2.2% | 1.8% | · | 0.08% |
Liquidity & Solvency 4
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.8 | 2.0 | · | 1.7 | 1.6 | 3.4 | · | 4.3 | 2.4 | 2.3 | · | 2.1 | 3.2 | 3.1 | · | 3.2 | |
| Quick Ratio | 1.1 | 1.2 | · | 0.9 | 0.9 | 2.1 | · | 2.9 | 1.3 | 1.4 | · | 1.2 | 2.0 | 2.0 | · | 1.8 | |
| Debt / Equity | 0.9 | 1.2 | · | 1.4 | 1.4 | 1.3 | · | 1.5 | 1.5 | 1.5 | · | 1.6 | 1.6 | 1.7 | · | 2.1 | |
| LT Debt / Equity | 0.7 | 1.0 | · | 1.1 | 1.2 | 1.3 | · | 1.5 | 1.4 | 1.4 | · | 1.5 | 1.6 | 1.7 | · | 2.1 |
Efficiency 2
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 1.5 | 1.4 | · | 1.5 | 1.5 | 1.3 | · | 1.6 | 1.6 | 1.4 | · | 1.6 | 1.6 | 1.5 | · | 1.7 |
Valuation (TTM) 13
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.45B | $4.14B | · | $4.12B | $4.02B | $3.88B | · | $3.95B | $3.86B | $3.72B | · | $3.76B | $3.72B | $3.58B | · | $3.53B | |
| Net Income TTM | $19M | $-266M | · | $-345M | $-427M | $276M | · | $516M | $405M | $306M | · | $301M | $189M | $86M | · | $-36M | |
| Market Cap | $15.61B | $11.85B | · | $8.01B | $6.44B | $7.65B | · | $6.73B | $6.59B | $7.59B | · | $8.15B | · | · | · | · | |
| Enterprise Value | $18.35B | $15.36B | · | $12.04B | $10.61B | $11.16B | · | $10.63B | $10.94B | $11.86B | · | $12.53B | · | · | · | · | |
| P/E | -535.5 | -39.8 | · | -22.9 | -14.4 | 29.8 | · | 14.2 | 18.0 | 26.9 | · | 29.5 | 44.3 | 111.7 | · | -225.9 | |
| P/S | 3.5 | 2.9 | · | 1.9 | 1.6 | 2.0 | · | 1.7 | 1.7 | 2.0 | · | 2.2 | · | · | · | · | |
| P/B | 3.3 | 2.6 | · | 2.0 | 1.7 | 1.8 | · | 1.6 | 1.8 | 2.1 | · | 2.3 | · | · | · | · | |
| P / Cash Flow | · | 29.0 | · | · | · | 17.8 | · | · | · | 28.4 | · | · | · | · | · | · | |
| P / FCF | · | 30.5 | · | · | · | 18.4 | · | · | · | 29.2 | · | · | · | · | · | · | |
| EV / EBITDA | 73.9 | 45.6 | · | 209.4 | -15.5 | -199.6 | · | 40.8 | 54.9 | 179.1 | · | 72.7 | · | · | · | · | |
| EV / FCF | · | 39.5 | · | · | · | 26.8 | · | · | · | 45.5 | · | · | · | · | · | · | |
| EV / Revenue | 4.1 | 3.7 | · | 2.9 | 2.6 | 2.9 | · | 2.7 | 2.8 | 3.2 | · | 3.3 | · | · | · | · | |
| Earnings Yield | -0.19% | -2.5% | · | -4.4% | -6.9% | 3.4% | · | 7.0% | 5.5% | 3.7% | · | 3.4% | 2.3% | 0.90% | · | -0.44% |
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
Income Statement
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Revenue | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B |
| Net Income | $-356M | $560M | $415M | $-224M | $-330M |
| Diluted EPS | $-5.84 | $8.65 | $6.10 | $-3.58 | $-5.52 |
Latest News Recent headlines mentioning this company
My Metrics Your personal watchlist — selected rows from Full Fundamentals
📊
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Institutional owners (13F) 690 filers · $9.8B total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 143 (+46 vs prior Q) | 56 (-21 vs prior Q) | 220 (+20 vs prior Q) | 190 (+12 vs prior Q) | +4.4M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| FMR LLC | $846,470,147 | 3,512,762 | 8.60% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $731,636,247 | 3,036,213 | 7.43% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $657,763,761 | 2,729,650 | 6.68% | Shares |
| Capital World Investors | $650,043,082 | 2,697,610 | 6.60% | Shares |
| STATE STREET CORP | $481,895,662 | 1,999,816 | 4.89% | Shares |
| FULLER & THALER ASSET MANAGEMENT, INC. | $394,839,917 | 1,638,544 | 4.01% | Shares |
| DIMENSIONAL FUND ADVISORS LP | $390,196,222 | 1,619,274 | 3.96% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $297,928,728 | 1,236,065 | 3.03% | Shares |
| AMERIPRISE FINANCIAL INC | $260,580,996 | 1,081,421 | 2.65% | Shares |
| CITADEL ADVISORS LLC | $242,578,716 | 1,006,676 | 2.46% | Shares |
| Swedbank AB | $233,208,837 | 967,792 | 2.37% | Shares |
| MILLENNIUM MANAGEMENT LLC | $184,072,164 | 763,880 | 1.87% | Shares |
| VICTORY CAPITAL MANAGEMENT INC | $165,478,678 | 686,719 | 1.68% | Shares |
| NORGES BANK | $158,279,458 | 656,843 | 1.61% | Shares |
| RENAISSANCE TECHNOLOGIES LLC | $135,442,731 | 562,073 | 1.38% | Shares |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $129,891,746 | 539,037 | 1.32% | Shares |
| Allianz Asset Management GmbH | $122,925,785 | 510,129 | 1.25% | Shares |
| GMT Capital Corp | $109,279,895 | 453,500 | 1.11% | Shares |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | $105,278,106 | 436,893 | 1.07% | Shares |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $103,893,734 | 431,148 | 1.06% | Shares |
| TWO SIGMA INVESTMENTS, LP | $96,439,086 | 400,212 | 0.98% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $95,008,929 | 394,277 | 0.96% | Shares |
| SYSTEMATIC FINANCIAL MANAGEMENT LP | $89,279,867 | 370,502 | 0.91% | Shares |
| Sofinnova Investments, Inc. | $88,036,221 | 365,341 | 0.89% | Shares |
| Polaris Capital Management, LLC | $79,270,937 | 328,966 | 0.81% | Shares |
| AMERICAN CENTURY COMPANIES INC | $77,695,234 | 322,427 | 0.79% | Shares |
| Bank of New York Mellon Corp | $76,961,481 | 319,382 | 0.78% | Shares |
| GOLDENTREE ASSET MANAGEMENT LP | $70,838,675 | 294,435 | 0.72% | Shares |
| Qube Research & Technologies Ltd | $70,056,003 | 290,725 | 0.71% | Shares |
| FRONTIER CAPITAL MANAGEMENT CO LLC | $66,815,854 | 277,279 | 0.68% | Shares |
| Quantinno Capital Management LP | $65,906,960 | 273,506 | 0.67% | Shares |
| Boston Trust Walden Corp | $64,110,068 | 266,050 | 0.65% | Shares |
| BANK OF AMERICA CORP /DE/ | $60,589,497 | 251,440 | 0.62% | Shares |
| Tri Locum Partners LP | $53,427,868 | 221,720 | 0.54% | Shares |
| Iron Triangle Partners LP | $49,668,900 | 292,170 | 0.50% | Shares |
| ARGENT CAPITAL MANAGEMENT LLC | $48,211,350 | 200,072 | 0.49% | Shares |
| GOLDMAN SACHS GROUP INC | $45,527,185 | 188,933 | 0.46% | Shares |
| PERCEPTIVE ADVISORS LLC | $40,964,900 | 170,000 | 0.42% | Shares |
| RAYMOND JAMES FINANCIAL INC | $39,434,259 | 163,648 | 0.40% | Shares |
| RHUMBLINE ADVISERS | $39,282,382 | 163,018 | 0.40% | Shares |
| Holocene Advisors, LP | $38,794,001 | 160,991 | 0.39% | Shares |
| Saturn V Capital Management LP | $38,781,230 | 160,938 | 0.39% | Shares |
| PFM Health Sciences, LP | $38,740,265 | 160,768 | 0.39% | Shares |
| Retirement Systems of Alabama | $38,473,993 | 159,663 | 0.39% | Shares |
| Woodline Partners LP | $36,165,501 | 150,083 | 0.37% | Shares |
| LOOMIS SAYLES & CO L P | $35,355,338 | 146,721 | 0.36% | Shares |
| Pictet Asset Management Holding SA | $35,115,175 | 147,599 | 0.36% | Shares |
| PRINCIPAL FINANCIAL GROUP INC | $34,163,762 | 141,776 | 0.35% | Shares |
| STIFEL FINANCIAL CORP | $33,583,066 | 139,365 | 0.34% | Shares |
| BNP PARIBAS FINANCIAL MARKETS | $33,026,625 | 137,057 | 0.34% | Shares |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $32,383,478 | 134,388 | 0.33% | Shares |
| California Public Employees Retirement System | $30,759,098 | 127,647 | 0.31% | Shares |
| WEDGE CAPITAL MANAGEMENT L L P/NC | $30,249,134 | 160,006 | 0.31% | Shares |
| Robeco Institutional Asset Management B.V. | $28,340,967 | 117,612 | 0.29% | Shares |
| Gotham Asset Management, LLC | $26,992,014 | 112,014 | 0.27% | Shares |
| Aristotle Capital Management, LLC | $26,915,626 | 111,697 | 0.27% | Shares |
| Swiss National Bank | $26,771,767 | 111,100 | 0.27% | Shares |
| STOREBRAND ASSET MANAGEMENT AS | $26,309,828 | 109,183 | 0.27% | Shares |
| CANADA PENSION PLAN INVESTMENT BOARD | $25,928,372 | 107,600 | 0.26% | Shares |
| PANAGORA ASSET MANAGEMENT INC | $25,286,187 | 104,935 | 0.26% | Shares |
| BlackRock, Inc. | $23,889,284 | 99,138 | 0.24% | Shares |
| Perpetual Ltd | $23,733,376 | 98,491 | 0.24% | Shares |
| WELLINGTON MANAGEMENT GROUP LLP | $23,658,917 | 98,182 | 0.24% | Shares |
| MORGAN STANLEY | $23,519,795 | 97,604 | 0.24% | Shares |
| Man Group plc | $23,299,389 | 96,690 | 0.24% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $22,868,053 | 94,900 | 0.23% | Put option |
| ENVESTNET ASSET MANAGEMENT INC | $22,061,835 | 91,554 | 0.22% | Shares |
| Rhenman & Partners Asset Management AB | $21,070,417 | 87,440 | 0.21% | Shares |
| Aberdeen Group plc | $20,146,538 | 83,606 | 0.20% | Shares |
| Amundi | $19,114,464 | 79,323 | 0.19% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $18,916,145 | 78,500 | 0.19% | Call option |
| Schonfeld Strategic Advisors LLC | $18,620,232 | 77,272 | 0.19% | Shares |
| FIRST TRUST ADVISORS LP | $18,149,860 | 75,320 | 0.18% | Shares |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $17,765,513 | 73,725 | 0.18% | Shares |
| LAZARD ASSET MANAGEMENT LLC | $16,768,620 | 69,588 | 0.17% | Shares |
| Longaeva Partners L.P. | $16,576,808 | 68,792 | 0.17% | Shares |
| Simplify Asset Management Inc. | $16,520,903 | 68,560 | 0.17% | Shares |
| ALLIANCEBERNSTEIN L.P. | $16,497,448 | 87,265 | 0.17% | Shares |
| Distillate Capital Partners LLC | $16,167,159 | 67,092 | 0.16% | Shares |
| SEB Asset Management AB | $15,890,255 | 65,943 | 0.16% | Shares |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $15,380,484 | 64,700 | 0.16% | Shares |
| SEI INVESTMENTS CO | $14,931,224 | 61,963 | 0.15% | Shares |
| Illinois Municipal Retirement Fund | $14,911,947 | 61,883 | 0.15% | Shares |
| Tweedy, Browne Co LLC | $14,494,105 | 60,149 | 0.15% | Shares |
| MARTINGALE ASSET MANAGEMENT L P | $14,335,788 | 59,492 | 0.15% | Shares |
| DeepCurrents Investment Group LLC | $14,132,168 | 58,647 | 0.14% | Shares |
| WORLDQUANT MILLENNIUM ADVISORS LLC | $13,348,774 | 55,396 | 0.14% | Shares |
| VANGUARD ASSET MANAGEMENT, Ltd | $12,952,138 | 53,750 | 0.13% | Shares |
| ExodusPoint Capital Management, LP | $12,819,845 | 53,201 | 0.13% | Shares |
| Squarepoint Ops LLC | $12,807,074 | 53,148 | 0.13% | Shares |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $12,034,356 | 63,657 | 0.12% | Shares |
| ALGERT GLOBAL LLC | $11,749,697 | 48,760 | 0.12% | Shares |
| CASTLEARK MANAGEMENT LLC | $11,306,312 | 46,920 | 0.11% | Shares |
| CITADEL ADVISORS LLC | $11,253,299 | 46,700 | 0.11% | Call option |
| RENAISSANCE GROUP LLC | $11,221,601 | 46,568 | 0.11% | Shares |
| Nuveen, LLC | $11,184,623 | 46,415 | 0.11% | Shares |
| PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO | $10,859,795 | 45,067 | 0.11% | Shares |
| Foundry Partners, LLC | $10,730,160 | 86,429 | 0.11% | Shares |
| Legal & General Group Plc | $10,402,916 | 43,171 | 0.11% | Shares |
| DEAN INVESTMENT ASSOCIATES, LLC | $10,273,274 | 42,633 | 0.10% | Shares |
Company insiders 50 insiders · 4 officers · 4 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Renee D Gala | President & CEO | June 30, 2026 F | 147,361 | 0 | 0 | $0 |
| Philip L Johnson | EVP & Chief Financial Officer | June 30, 2026 F | 56,431 | 0 | 0 | $0 |
| Neena M Patil | EVP & Chief Legal Officer | June 30, 2026 F | 48,871 | 0 | 2 | $-560,664 |
| Robert Iannone | EVP, Global Head of R&D & CMO | June 30, 2026 F | 85,107 | 0 | 0 | $0 |
| Bryan C Cressey | Director | March 9, 2012 S | 27,631 | 0 | 0 | $0 |
| Zilkha M Nathaniel | Director | March 10, 2011 A | — | 0 | 0 | $0 |
| Alexander E Albert | Director | Aug. 15, 2008 A | — | 0 | 0 | $0 |
| Patel Jaimin | Director | Aug. 15, 2007 A | — | 0 | 0 | $0 |
| Patrick Kennedy | — | Aug. 5, 2026 A | 8,307 | 0 | 0 | $0 |
| Samantha Pearce | — | Aug. 5, 2026 F | 47,131 | 0 | 1 | $-1,625,977 |
| Mark Douglas Smith | — | Aug. 5, 2026 A | 11,285 | 0 | 1 | $-266,746 |
| Jennifer E. Cook | — | Aug. 5, 2026 A | 12,442 | 0 | 0 | $0 |
| Laura Hamill | — | Aug. 5, 2026 A | 8,538 | 0 | 0 | $0 |
| Heather Ann Mcsharry | — | Aug. 5, 2026 A | 20,054 | 0 | 0 | $0 |
| Seamus Mulligan | — | Aug. 5, 2026 A | 1,184,633 | 0 | 0 | $0 |
| Rick E Winningham | — | Aug. 5, 2026 A | 11,172 | 0 | 2 | $-1,656,873 |
| Patrick G. Enright | — | Aug. 5, 2026 A | 22,984 | 0 | 0 | $0 |
| Bruce C Cozadd | — | Aug. 5, 2026 A | 362,287 | 0 | 20 | $-25,646,326 |
| Ted W Love | — | Aug. 5, 2026 A | 3,132 | 0 | 0 | $0 |
| Norbert G Riedel | — | Aug. 5, 2026 A | 8,629 | 0 | 1 | $-655,680 |
| Kenneth W O'Keefe | — | Dec. 2, 2025 F | 25,811 | 0 | 0 | $0 |
| Daniel N Swisher JR | — | Jan. 3, 2019 F | 16,512 | 0 | 0 | $0 |
| Suzanne Sawochka Hooper | — | Dec. 14, 2018 M | 41,184 | 0 | 0 | $0 |
| Matthew P. Young | — | Nov. 23, 2018 S | 32,068 | 0 | 0 | $0 |
| MILLER MICHAEL PATRICK | — | Nov. 13, 2018 S | 24,972 | 0 | 0 | $0 |
| Paul Treacy | — | Aug. 10, 2018 S | 17,458 | 0 | 0 | $0 |
| Elmar Schnee | — | Aug. 9, 2018 A | 6,094 | 0 | 0 | $0 |
| Peter Gray | — | Aug. 9, 2018 A | 8,182 | 0 | 0 | $0 |
| Catherine A. Sohn | — | Aug. 9, 2018 A | 7,654 | 0 | 0 | $0 |
| Paul L Berns | — | Aug. 9, 2018 A | 6,772 | 0 | 0 | $0 |
| Karen J Wilson | — | May 11, 2018 S | 15,757 | 0 | 0 | $0 |
| Karen L. Smith | — | March 5, 2018 F | 28,474 | 0 | 0 | $0 |
| Iain Mcgill | — | March 5, 2018 F | 22,048 | 0 | 0 | $0 |
| Russell J. Cox | — | March 6, 2017 F | 52,795 | 0 | 0 | $0 |
| Jeffrey K Tobias | — | March 5, 2015 F | 38,484 | 0 | 0 | $0 |
| Fintan Keegan | — | July 8, 2014 M | 31,750 | 0 | 0 | $0 |
| Kathryn E Falberg | — | March 5, 2014 F | 133,387 | 0 | 0 | $0 |
| James C Momtazee | — | Aug. 13, 2013 S | 17,315 | 0 | 0 | $0 |
| Carol A Gamble | — | March 9, 2012 S | 32,213 | 0 | 0 | $0 |
| Alan Sebulsky | — | March 9, 2012 S | 54,355 | 0 | 0 | $0 |
| Samuel D Colella | — | Jan. 11, 2012 M | 38,347 | 0 | 0 | $0 |
| Michael W Michelson | — | Jan. 11, 2012 M | 13,885 | 0 | 0 | $0 |
| Mark G. Eller | — | Aug. 13, 2011 M | 4,151 | 0 | 0 | $0 |
| Michael A. Desjardin | — | Aug. 13, 2011 M | 14,574 | 0 | 0 | $0 |
| Janne Lt Wissel | — | May 31, 2011 J | 48,544 | 0 | 0 | $0 |
| Joan Colligan | — | Nov. 30, 2010 J | 14,424 | 0 | 0 | $0 |
| Robert M Myers | — | Nov. 30, 2010 J | 156,898 | 0 | 0 | $0 |
| James B Tananbaum | — | Aug. 25, 2010 A | 21,366 | 0 | 0 | $0 |
| Samuel R Saks | — | Jan. 21, 2009 A | 358,868 | 0 | 0 | $0 |
| Matthew K Fust | — | Nov. 28, 2008 J | 58,948 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
Activists & 5%+ owners 6 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Jazz Pharmaceuticals Public Limited Company, Jazz Financing I Limited, Jazz Investments II Limited, Jazz Pharmaceuticals Italy S.p.A. ×4 filings | June 20, 2014 | — | Initial filing | — | SEC |
| KKR JP LLC, KKR Millennium Fund L.P., KKR Associates Millennium L.P., KKR Millennium GP LLC, KKR Fund Holdings L.P., KKR Fund Holdings GP Limited, KKR Group Holdings L.P., KKR Group Limited, KKR & Co. L.P., KKR Management LLC, KKR JP III LLC, KKR Partners III, L.P., KKR III GP LLC, Henry R. Kravis, George R. Roberts ×3 filings | March 12, 2013 | — | Initial filing | — | SEC |
| Longitude Capital Partners, LLC, Longitude Venture Partners, L.P., Longitude Capital Associates, L.P., Patrick G. Enright, Juliet Tammenoms Bakker ×3 filings | March 14, 2012 | — | Initial filing | Capital structure | SEC |
| Longitude Capital Partners, LLC (2), Longitude Venture Partners, L.P. (2), Longitude Capital Associates, L.P. (2), Patrick G. Enright (2), Juliet Tammenoms Bakker (2) ×3 filings | Sept. 30, 2011 | — | Initial filing | — | SEC |
| Azur Pharma Limited | Sept. 28, 2011 | — | Initial filing | M&A / sale | SEC |
| Jazz Pharmaceuticals, Inc., KKR Millennium Fund L.P., KKR Associates Millennium L.P., KKR Millennium GP LLC, KKR Partners III, L.P., KKR III GP LLC, KKR JP LLC, KKR JP III LLC | April 28, 2005 | — | Initial filing | M&A / sale | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF ownership Held by 72 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| IHE · iShares Trust | 3.55% | 224,123 SH | Aug. 8, 2026 | Daily |
| PJP · Invesco Exchange-Traded Fund Trust | 2.75% | 54,246 SH | Aug. 8, 2026 | Daily |
| PTH · Invesco Exchange-Traded Fund Trust | 1.88% | 18,101 SH | Aug. 8, 2026 | Daily |
| PILL · Direxion Shares ETF Trust | 1.47% | 931 NS | April 30, 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 1.10% | 3,412 SH | Aug. 8, 2026 | Daily |
| RFG · Invesco Exchange-Traded Fund Trust | 1.01% | 14,167 SH | Aug. 8, 2026 | Daily |
| IJK · iShares Trust | 0.86% | 367,117 SH | Aug. 8, 2026 | Daily |
| IVOG · VANGUARD ADMIRAL FUNDS | 0.79% | 61,910 SH | Aug. 8, 2026 | Daily |
| PDP · Invesco Exchange-Traded Fund Trust | 0.64% | 37,430 SH | Aug. 8, 2026 | Daily |
| XJH · iShares Trust | 0.51% | 8,479 SH | Aug. 8, 2026 | Daily |
| ISCV · iShares Trust | 0.50% | 13,756 SH | Aug. 8, 2026 | Daily |
| LSVD · ADVISORS' INNER CIRCLE FUND | 0.50% | 14,803 NS | April 30, 2026 | N-PORT |
| AVMV · AMERICAN CENTURY ETF TRUST | 0.49% | 12,809 NS | May 31, 2026 | N-PORT |
| QVMM · Invesco Exchange-Traded Fund Trust … | 0.48% | 8,322 SH | Aug. 8, 2026 | Daily |
| IJH · iShares Trust | 0.44% | 2,164,793 SH | Aug. 8, 2026 | Daily |
| SMMV · iShares Trust | 0.41% | 4,673 SH | Aug. 8, 2026 | Daily |
| IVOO · VANGUARD ADMIRAL FUNDS | 0.41% | 101,353 SH | Aug. 8, 2026 | Daily |
| VFVA · VANGUARD WELLINGTON FUND | 0.32% | 11,363 SH | Aug. 8, 2026 | Daily |
| VBR · VANGUARD INDEX FUNDS | 0.31% | 867,777 SH | Aug. 8, 2026 | Daily |
| AVLV · AMERICAN CENTURY ETF TRUST | 0.28% | 154,718 NS | May 31, 2026 | N-PORT |
| VFMF · VANGUARD WELLINGTON FUND | 0.28% | 8,083 SH | Aug. 8, 2026 | Daily |
| IYH · iShares Trust | 0.25% | 35,721 SH | Aug. 8, 2026 | Daily |
| ISCB · iShares Trust | 0.25% | 2,794 SH | Aug. 8, 2026 | Daily |
| DFAS · Dimensional ETF Trust | 0.25% | 169,973 NS | April 30, 2026 | N-PORT |
| MIDU · Direxion Shares ETF Trust | 0.24% | 1,006 NS | April 30, 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0.24% | 19,561 SH | Aug. 8, 2026 | Daily |
| NUSC · Nushares ETF Trust | 0.23% | 14,796 NS | April 30, 2026 | N-PORT |
| ESML · iShares Trust | 0.23% | 25,562 SH | Aug. 8, 2026 | Daily |
| AVMC · AMERICAN CENTURY ETF TRUST | 0.20% | 3,508 NS | May 31, 2026 | N-PORT |
| SMMD · iShares Trust | 0.20% | 29,882 SH | Aug. 8, 2026 | Daily |
| VHT · VANGUARD WORLD FUND | 0.20% | 166,548 SH | Aug. 8, 2026 | Daily |
| RWK · Invesco Exchange-Traded Fund Trust … | 0.20% | 10,307 SH | Aug. 8, 2026 | Daily |
| VXF · VANGUARD INDEX FUNDS | 0.17% | 719,903 SH | Aug. 8, 2026 | Daily |
| VB · VANGUARD INDEX FUNDS | 0.17% | 1,366,973 SH | Aug. 8, 2026 | Daily |
| DFAT · Dimensional ETF Trust | 0.17% | 113,983 NS | April 30, 2026 | N-PORT |
| DFSV · Dimensional ETF Trust | 0.16% | 59,597 NS | April 30, 2026 | N-PORT |
| AVUQ · AMERICAN CENTURY ETF TRUST | 0.15% | 1,679 NS | May 31, 2026 | N-PORT |
| IWS · iShares Trust | 0.15% | 89,654 SH | Aug. 8, 2026 | Daily |
| AVIE · AMERICAN CENTURY ETF TRUST | 0.14% | 59 NS | May 31, 2026 | N-PORT |
| WSML · iShares Trust | 0.13% | 3,473 SH | Aug. 8, 2026 | Daily |
| AVSU · AMERICAN CENTURY ETF TRUST | 0.13% | 2,492 NS | May 31, 2026 | N-PORT |
| IWR · iShares Trust | 0.11% | 243,081 SH | Aug. 8, 2026 | Daily |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0.10% | 3,276 SH | Aug. 8, 2026 | Daily |
| XT · iShares Trust | 0.09% | 13,696 SH | Aug. 8, 2026 | Daily |
| AVLC · AMERICAN CENTURY ETF TRUST | 0.08% | 4,239 NS | May 31, 2026 | N-PORT |
| AVUS · AMERICAN CENTURY ETF TRUST | 0.08% | 42,911 NS | May 31, 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0.07% | 2,294 NS | May 31, 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0.07% | 147,813 NS | April 30, 2026 | N-PORT |
| DFUV · Dimensional ETF Trust | 0.06% | 45,962 NS | April 30, 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0.05% | 7,081 NS | April 30, 2026 | N-PORT |